1. Market Research
  2. > Liver Diseases – Pipeline Review, H1 2013

Liver Diseases – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 331 pages

Liver Diseases – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Liver Diseases - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Liver Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Diseases. Liver Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Liver Diseases.
- A review of the Liver Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Diseases pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Liver Diseases.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Diseases pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Liver Diseases - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Liver Diseases Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Liver Diseases 12
Liver Diseases Therapeutics under Development by Companies 14
Liver Diseases Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 24
Comparative Analysis 24
Mid Clinical Stage Products 25
Comparative Analysis 25
Early Clinical Stage Products 26
Comparative Analysis 26
Discovery and Pre-Clinical Stage Products 27
Comparative Analysis 27
Liver Diseases Therapeutics - Products under Development by Companies 28
Liver Diseases Therapeutics - Products under Investigation by Universities/Institutes 35
Companies Involved in Liver Diseases Therapeutics Development 37
Bristol-Myers Squibb Company 37
Genzyme Corporation 38
F. Hoffmann-La Roche Ltd. 39
Isis Pharmaceuticals, Inc. 40
Gilead Sciences, Inc. 41
Merck and Co., Inc. 42
FASgen, Inc. 43
Novo Nordisk A/S 44
Bioneer Corporation 45
ViaCord 46
Mochida Pharmaceutical Co., Ltd. 47
FibroGen, Inc. 48
Novartis AG 49
Daewoong Pharmaceutical Co., Ltd. 50
Hadasit Medical Research Services and Development Ltd 51
Silence Therapeutics plc. 52
EpiCept Corporation 53
GW Pharmaceuticals plc 54
Genfit 55
LifeCycle Pharma A/S 56
Orchid Chemicals and Pharmaceuticals Ltd 57
PAION AG 58
La Jolla Pharmaceutical Company 59
Alnylam Pharmaceuticals, Inc 60
Proteonomix, Inc. 61
Immuron Limited 62
LG Life Sciences, Ltd 63
Phynova Group Ltd 64
Raptor Pharmaceuticals Corp. 65
Digna Biotech, S.L. 66
StemCells, Inc. 67
VistaGen Therapeutics , Inc. 68
Biotecnol SA 69
Jenrin Discovery, Inc. 70
Phenex Pharmaceuticals AG 71
Wellstat Therapeutics Corporation 72
Ventria Bioscience 73
Metabolic Solutions Development Co. 74
TetraLogic Pharmaceuticals 75
IC-MedTech, Inc. 76
Tranzyme Pharma, Inc. 77
Conatus Pharmaceuticals Inc. 78
GenKyoTex S.A. 79
Angion Biomedica Corp. 80
REPLICor Inc. 81
Virobay Inc. 82
Intercept Pharmaceuticals, Inc. 83
Obio Pharmaceutical Holdings Limited. 84
Jenken Biosciences, Inc 85
Limerick BioPharma, Inc. 86
GNI, LTD. 87
NasVax Ltd. 88
Lee's Pharmaceutical Holdings Limited 89
Ascenion GmbH 90
MAKScientific, LLC 91
GENEXTRA S.p.A. 92
Riken 93
Galmed International Ltd. 94
FCB-Pharmicell Co.,Ltd. 95
BiOrion Technologies B.V. 96
Connexios Life Sciences Pvt. Ltd. 97
ACROVIS biostructures GmbH 98
Liver Diseases - Therapeutics Assessment 99
Assessment by Monotherapy Products 99
Assessment by Combination Products 100
Assessment by Route of Administration 101
Assessment by Molecule Type 103
Drug Profiles 106
MK-4074 - Drug Profile 106
siponimod - Drug Profile 107
(AHU-377 + valsartan) - Drug Profile 109
FG-3019 - Drug Profile 111
GFT-505 - Drug Profile 113
GFT-505 - Drug Profile 115
ulimorelin hydrochloride - Drug Profile 117
PYN-22 - Drug Profile 119
P-17 - Drug Profile 120
disitertide - Drug Profile 121
Cardiotrophin-1 - Drug Profile 123
PN-2XXX - Drug Profile 125
cysteamine - Drug Profile 126
Human Liver Engrafting Cells - Drug Profile 129
GM-CT-01 - Drug Profile 131
VBY-376 - Drug Profile 134
BB-3 - Drug Profile 135
REP-9-AC - Drug Profile 137
Necrostatin Program - Drug Profile 139
JD-2000 Series - Drug Profile 140
JD-5000 Series - Drug Profile 141
JD-6000 Series - Drug Profile 142
STNM-09 - Drug Profile 143
obeticholic acid - Drug Profile 144
liraglutide - Drug Profile 147
remimazolam - Drug Profile 149
FAS-89B - Drug Profile 151
GCS-100 - Drug Profile 152
Aramchol - Drug Profile 154
GKT-137831 - Drug Profile 155
tolvaptan - Drug Profile 156
JKB-121 - Drug Profile 158
JKB-119 - Drug Profile 159
AK-20 - Drug Profile 160
nitric oxide - Drug Profile 161
INT-767 - Drug Profile 162
emricasan - Drug Profile 164
RO-5093151 - Drug Profile 166
silibinin - Drug Profile 168
irbesartan - Drug Profile 169
tacrolimus - Drug Profile 170
simtuzumab - Drug Profile 172
Cholic Acid - Drug Profile 174
Adult Human Mesenchymal Stem Cells - Drug Profile 175
losartan - Drug Profile 176
Allogeneic Bone Marrow Mesenchymal Stem Cells - Drug Profile 177
MSDC-0602 - Drug Profile 178
CIGB-500 - Drug Profile 180
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile 181
atorvastatin calcium - Drug Profile 183
AB-0023 - Drug Profile 184
AM-095 - Drug Profile 185
Cannabidiol - Drug Profile 186
Anti-aCD3 Mab - Drug Profile 187
Anti-aCD3 Mab - Drug Profile 189
HYPER-IL-6 - Drug Profile 191
FXR-Agonist - Drug Profile 192
PanCyte - Drug Profile 193
ALF-5755 - Drug Profile 194
ALF-5755 - Drug Profile 195
Cytopro - Drug Profile 196
GM-CT-02 - Drug Profile 197
GR-MD-02 - Drug Profile 198
GR-MD-01 - Drug Profile 200
oltipraz - Drug Profile 201
RP-104 - Drug Profile 202
gadolinium chloride - Drug Profile 203
carbamazepine - Drug Profile 204
IMM-124E - Drug Profile 205
DWP-10292 - Drug Profile 206
deferasirox - Drug Profile 207
Px-102 - Drug Profile 208
CNXFC-010 - Drug Profile 209
UMK-121 - Drug Profile 210
ISIS-AATRx - Drug Profile 211
NHP-554L - Drug Profile 212
pioglitazone hydrochloride + Mesenchymal Stem Cell Transplantation - Drug Profile 213
cholecalciferol - Drug Profile 214
levocarnitine_ - Drug Profile 215
ISIS-DGAT2Rx - Drug Profile 216
ANG-4011 - Drug Profile 217
icosapent ethyl - Drug Profile 218
BLX-1002 - Drug Profile 219
tranilast - Drug Profile 220
F-573 - Drug Profile 221
F-573 - Drug Profile 222
F-351 - Drug Profile 223
Drug For Liver Diseases - Drug Profile 225
LJPC-201 - Drug Profile 226
LIM-0705 - Drug Profile 227
Cell Therapy For Liver Repair - Drug Profile 229
ANG-3298 - Drug Profile 230
F-652 - Drug Profile 231
ZK-006 - Drug Profile 232
LC-280126 - Drug Profile 233
Picroliv - Drug Profile 234
TAT-ARC - Drug Profile 235
NKT II Cell Modulator - Drug Profile 236
Cymac-001 - Drug Profile 238
optibumin Biosimilar - Drug Profile 239
VEN-140 - Drug Profile 240
TRPM7 Inhibitor Program - Drug Profile 241
Galectin-3 Inhibitors - Drug Profile 242
ALN-AAT - Drug Profile 243
1D-11 - Drug Profile 244
anakinra - Drug Profile 245
NoX-1/4 Inhibitors - Drug Profile 246
SR-9238 - Drug Profile 247
AMPK Activators For Fatty Liver Disease - Drug Profile 248
Nox Enzymes Inhibitors - Drug Profile 249
CT-140 - Drug Profile 250
Drug For Liver Fibrosis - Drug Profile 251
Compounds For Lung And Liver Disease - Drug Profile 252
mPTP Inhibitors - Drug Profile 253
p66Shc Protein Inhibitors - Drug Profile 254
Mesenchymal Stem Cells For Liver Fibrosis - Drug Profile 255
RXI-209 - Drug Profile 256
Drug For Acute Liver Failure - Drug Profile 257
Drug For Liver Regeneration - Drug Profile 258
MicroRNA-221 - Drug Profile 259
BOT-191 - Drug Profile 260
Antibody Drug For Hepatic Disease - Drug Profile 261
3-Deazaneplanocin A - Drug Profile 262
JD-5006 - Drug Profile 264
JD-5037 - Drug Profile 265
AM-6545 - Drug Profile 266
Liver Diseases Therapeutics - Drug Profile Updates 268
Liver Diseases Therapeutics - Discontinued Products 308
Liver Diseases Therapeutics - Dormant Products 309
Liver Diseases - Product Development Milestones 314
Featured News and Press Releases 314
Appendix 321
Methodology 321
Coverage 321
Secondary Research 321
Primary Research 321
Expert Panel Validation 321
Contact Us 322
Disclaimer 322



List of Tables

Number of Products Under Development for Liver Diseases, H1 2013 21
Products under Development for Liver Diseases - Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Development by Companies, H1 2013 (Contd..1) 25
Number of Products under Development by Companies, H1 2013 (Contd..2) 26
Number of Products under Development by Companies, H1 2013 (Contd..3) 27
Number of Products under Development by Companies, H1 2013 (Contd..4) 28
Number of Products under Development by Companies, H1 2013 (Contd..5) 29
Number of Products under Investigation by Universities/Institutes, H1 2013 31
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 32
Comparative Analysis by Late Stage Development, H1 2013 33
Comparative Analysis by Mid Clinical Stage Development, H1 2013 34
Comparative Analysis by Early Clinical Stage Development, H1 2013 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 36
Products under Development by Companies, H1 2013 37
Products under Development by Companies, H1 2013 (Contd..1) 38
Products under Development by Companies, H1 2013 (Contd..2) 39
Products under Development by Companies, H1 2013 (Contd..3) 40
Products under Development by Companies, H1 2013 (Contd..4) 41
Products under Development by Companies, H1 2013 (Contd..5) 42
Products under Development by Companies, H1 2013 (Contd..6) 43
Products under Investigation by Universities/Institutes, H1 2013 44
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 45
Bristol-Myers Squibb Company, H1 2013 46
Genzyme Corporation, H1 2013 47
F. Hoffmann-La Roche Ltd., H1 2013 48
Isis Pharmaceuticals, Inc., H1 2013 49
Gilead Sciences, Inc., H1 2013 50
Merck and Co., Inc., H1 2013 51
FASgen, Inc., H1 2013 52
Novo Nordisk A/S, H1 2013 53
Bioneer Corporation, H1 2013 54
ViaCord, H1 2013 55
Mochida Pharmaceutical Co., Ltd., H1 2013 56
FibroGen, Inc., H1 2013 57
Novartis AG, H1 2013 58
Daewoong Pharmaceutical Co., Ltd., H1 2013 59
Hadasit Medical Research Services and Development Ltd, H1 2013 60
Silence Therapeutics plc., H1 2013 61
EpiCept Corporation, H1 2013 62
GW Pharmaceuticals plc, H1 2013 63
Genfit, H1 2013 64
LifeCycle Pharma A/S, H1 2013 65
Orchid Chemicals and Pharmaceuticals Ltd, H1 2013 66
PAION AG, H1 2013 67
La Jolla Pharmaceutical Company, H1 2013 68
Alnylam Pharmaceuticals, Inc, H1 2013 69
Proteonomix, Inc., H1 2013 70
Immuron Limited, H1 2013 71
LG Life Sciences, Ltd, H1 2013 72
Phynova Group Ltd, H1 2013 73
Raptor Pharmaceuticals Corp., H1 2013 74
Digna Biotech, S.L., H1 2013 75
StemCells, Inc., H1 2013 76
VistaGen Therapeutics , Inc., H1 2013 77
Biotecnol SA, H1 2013 78
Jenrin Discovery, Inc., H1 2013 79
Phenex Pharmaceuticals AG, H1 2013 80
Wellstat Therapeutics Corporation, H1 2013 81
Ventria Bioscience, H1 2013 82
Metabolic Solutions Development Co., H1 2013 83
TetraLogic Pharmaceuticals, H1 2013 84
IC-MedTech, Inc., H1 2013 85
Tranzyme Pharma, Inc., H1 2013 86
Conatus Pharmaceuticals Inc., H1 2013 87
GenKyoTex S.A., H1 2013 88
Angion Biomedica Corp., H1 2013 89
REPLICor Inc., H1 2013 90
Virobay Inc., H1 2013 91
Intercept Pharmaceuticals, Inc., H1 2013 92
Obio Pharmaceutical Holdings Limited., H1 2013 93
Jenken Biosciences, Inc, H1 2013 94
Limerick BioPharma, Inc., H1 2013 95
GNI, LTD., H1 2013 96
NasVax Ltd., H1 2013 97
Lee's Pharmaceutical Holdings Limited, H1 2013 98
Ascenion GmbH, H1 2013 99
MAKScientific, LLC, H1 2013 100
GENEXTRA S.p.A., H1 2013 101
Riken, H1 2013 102
Galmed International Ltd., H1 2013 103
FCB-Pharmicell Co.,Ltd., H1 2013 104
BiOrion Technologies B.V., H1 2013 105
Connexios Life Sciences Pvt. Ltd., H1 2013 106
ACROVIS biostructures GmbH, H1 2013 107
Assessment by Monotherapy Products, H1 2013 108
Assessment by Combination Products, H1 2013 109
Assessment by Stage and Route of Administration, H1 2013 111
Assessment by Stage and Molecule Type, H1 2013 114
Liver Diseases Therapeutics - Drug Profile Updates 277
Liver Diseases Therapeutics - Discontinued Products 317
Liver Diseases Therapeutics - Dormant Products 318
Liver Diseases Therapeutics - Dormant Products (Contd..1) 319
Liver Diseases Therapeutics - Dormant Products (Contd..2) 320
Liver Diseases Therapeutics - Dormant Products (Contd..3) 321
Liver Diseases Therapeutics - Dormant Products (Contd..4) 322



List of Figures

Number of Products under Development for Liver Diseases, H1 2013 21
Products under Development for Liver Diseases - Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 30
Late Stage Products, H1 2013 33
Mid Clinical Stage Products, H1 2013 34
Early Clinical Stage Products, H1 2013 35
Discovery and Pre-Clinical Stage Products, H1 2013 36
Assessment by Monotherapy Products, H1 2013 108
Assessment by Combination Products, H1 2013 109
Assessment by Route of Administration, H1 2013 110
Assessment by Stage and Route of Administration, H1 2013 111
Assessment by Molecule Type, H1 2013 112
Assessment by Stage and Molecule Type, H1 2013 113

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.